Biotricity INC 8-K filings

Biotricity Inc. has entered into exchange agreements to convert existing common stock, options, and warrants into newly created Series C Preferred Stock.

Biotricity Inc. announced strong second quarter fiscal 2026 financial results, showcasing significant revenue growth, improved gross margins, and a substantial reduction in net loss, driven by operational efficiencies and strategic market expansion.

Biotricity announces strong Q3 fiscal year 2025 results, featuring record margins, revenues, and cash flows, driven by a 21.7% year-over-year sales increase.

Biotricity announced a 13% year-over-year revenue increase and significant margin improvements for the second quarter of fiscal year 2025, achieving positive cash flow in September on a current operating basis.

Biotricity Inc. held its annual meeting, electing four directors and ratifying its auditor, but rejecting a proposal for a stock issuance related to convertible preferred stock.

Biotricity Inc. has received notice of delisting from the Nasdaq Capital Market due to failure to maintain the minimum market value of listed securities, with trading suspended on August 5, 2024.

Biotricity Inc. has received a notification from Nasdaq that its stock price has fallen below the minimum bid price requirement, potentially leading to delisting.

Biotricity Inc. has successfully completed the second closing of its private placement, securing an additional $500,000 through the sale of Series B Preferred Stock.

Biotricity Inc. stockholders have approved a proposal for the issuance of securities in one or more non-public offerings at a special meeting held on July 12, 2024.

Biotricity Inc. has entered into a securities purchase agreement for a private placement of convertible preferred stock, raising an initial $500,000 with the possibility of up to $1.5 million more.

Biotricity Inc. issued 8,952,172 shares of common stock to investors following the conversion of Series A Convertible Preferred Stock on June 4, 2024.

Biotricity Inc. has amended its At-The-Market Offering Agreement with H.C. Wainwright & Co., LLC to facilitate the sale of up to $2.68 million of its common stock.

Biotricity Inc. has completed an additional closing of its Series B Preferred Stock, raising $645,455, bringing the total raised in this round to $2 million.

Biotricity Inc. received a delisting notice from Nasdaq for not holding an annual meeting and completed a second closing of a private placement for $354,545.

Biotricity has been granted an extension to maintain its Nasdaq listing, contingent on meeting specific milestones by July 29, 2024.

Biotricity Inc. has amended the terms of its Series B Convertible Preferred Stock, removing voting rights previously granted to holders.

Biotricity Inc. has entered into a securities purchase agreement for a private placement of convertible preferred stock, raising an initial $1 million with a potential for an additional $1 million.

Biotricity Inc. received a delisting notice from Nasdaq after failing to maintain the minimum market value of listed securities, but intends to appeal the decision.